Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036

The global Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 9.0% by 2036

SKU: PHA1394 Category: Therapeutic Drugs Code: PHA1394Pages: 363

Download Sample Form

"*" indicates required fields

Name*

Company*

Designation*

Job Title

Industry

Email*

Phone*

Address*

This field is hidden when viewing the form

Report Title

This field is hidden when viewing the form

Sample url

← Back to category Therapeutic Drugs

Description

Visiongain has published a new report, Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036, providing a comprehensive analysis of the global retinal diseases drugs market, including market size, growth drivers, competitive positioning, and revenue forecasts across disease indication, route of administration, drug type, treatment type, and end-user segments.

The global macular degeneration (AMD) and other retinal diseases drugs market is valued at US$12.46bn in 2026 and is forecast to reach US$29.47bn by 2036, at a CAGR of 9.0% over the forecast period.

This growth is driven by the rising prevalence of AMD and diabetic retinal disease in ageing populations, accelerating adoption of longer-acting anti-VEGF therapies, and expanding investment in next-generation treatment modalities including complement inhibitors, gene therapies, and sustained-release biologic platforms.

Access a Free Sample of This Report

Download a sample to explore:

Market forecasts and segment breakdowns
Competitive and company-level insights
Key trends shaping the market
Trade, policy, and supply chain analysis

Technological Innovation Driving Market Expansion

The retinal diseases market is entering a new phase of innovation as manufacturers focus on extending treatment durability, improving patient convenience, and expanding therapeutic options beyond conventional anti-VEGF monotherapy. Recent regulatory approvals, positive long-term clinical data, and rising investment in next-generation retinal therapeutics signal a clear shift toward treatments capable of reducing injection frequency while sustaining long-term visual outcomes.

The competitive landscape has strengthened considerably following the approval of extended-dosing anti-VEGF therapies such as EYLEA HD and encouraging real-world evidence supporting Vabysmo in neovascular retinal diseases. Complement inhibitors have established the first disease-modifying treatment options for geographic atrophy, while continued clinical progress in gene therapies is reinforcing the long-term potential of one-time interventions capable of substantially reducing treatment burden.

Innovation in retinal drug delivery is also creating opportunities for more precise and less invasive treatment. Development activity is focused on suprachoroidal delivery systems, subretinal administration, hydrogel implants, microneedle-enabled ocular delivery, and non-viral gene-delivery platforms designed to improve drug penetration and sustained retinal exposure, supporting more personalised treatment strategies and reducing procedural dependence.

Trade, Policy & Supply Chain Dynamics

S. trade tariffs could increase the cost of manufacturing and supplying anti-VEGF agents, complement inhibitors, intravitreal injections, and emerging gene and cell therapies.
Higher costs for imported biologic inputs, prefilled syringes, sterile packaging, and specialised cold-chain components may pressure margins, delay product launches, and raise the overall cost of retinal treatment.
Established manufacturers are expected to mitigate disruption through inventory reserves, diversified sourcing strategies, and increased domestic production capacity.
Smaller biotechnology firms and biosimilar developers could face more pronounced cost pressures and supply chain constraints, potentially affecting competitiveness and slowing market entry.
Despite tariff pressures, demand for therapies treating AMD, diabetic macular oedema, diabetic retinopathy, and retinal vein occlusion is expected to remain resilient, as treatment delays can lead to irreversible vision loss.

Commercial Impact

Cost pressure: Tariffs on biologic inputs, sterile manufacturing components, and cold-chain infrastructure are increasing production costs and affecting procurement economics for manufacturers and healthcare providers
Supply chain shifts: Companies are diversifying sourcing strategies and expanding domestic manufacturing investment to reduce dependency on imported biologic materials and ocular drug-delivery components
Biosimilar dynamics: Tariff-related cost pressure may be particularly pronounced for biosimilar developers where pricing competitiveness and development expenditure are critical to market entry and positioning
Competitive positioning: Manufacturers with diversified supply networks and established domestic production capacity are better positioned to maintain supply continuity and protect margins

Company Intelligence

The AMD and retinal diseases drugs market is characterised by a mix of large pharmaceutical companies, specialist ophthalmology developers, and biosimilar manufacturers competing across clinical pipeline breadth, treatment durability, and drug-delivery innovation.

Leading companies including Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Novartis, Bayer AG, and Biogen are strengthening their positions through extended-dosing programme development, biosimilar defence strategies, and investment in next-generation complement and gene therapy platforms.

Competition is increasingly defined by:

Treatment durability and extended dosing interval capability across anti-VEGF programmes
Pipeline breadth across complement inhibition, gene therapy, and sustained-release biologic platforms
Biosimilar development and interchangeability credentials in maturing anti-VEGF markets
Drug-delivery innovation enabling less invasive and more targeted retinal treatment

This report analyses how competitive positioning is evolving across 17 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

What is the projected size of the AMD and retinal diseases drugs market by 2036?
Which segments and regions will drive growth?
How will longer-acting therapies, complement inhibitors, and gene therapies reshape the competitive landscape?
What is the impact of U.S. trade tariffs on manufacturing costs and biosimilar market entry?
Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

Global AMD and retinal diseases drugs market analysis
Revenue forecasts to 2036
Segment-level modelling across disease indication, route of administration, drug type, treatment type, and end user
Regional and national market forecasts across five regions and 21 leading national markets
Competitive intelligence on 17 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Disease Indication

AMD
Diabetic Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Others

By Route of Administration

Intravitreal
Intravenous
Others

By Drug Type

Branded Drugs (Eylea, Lucentis, Vabysmo, Others)
Generic Drugs

By Treatment Type

Anti-VEGF Agents
Complement Pathway Inhibitors
Gene & Cell Therapies
Dietary Supplements and Antioxidants
Others

By End User

Hospitals
Ambulatory Surgical Centres
Speciality Clinics
Home Healthcare
Others

Geographic Coverage

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of 17 leading companies, including:

Astellas Pharma
Bayer AG
Biocon
Biogen
Chengdu Kanghong Biotech
Hoffmann-La Roche Ltd
Formycon AG
Intas Pharmaceuticals
Kodiak Sciences
Novartis AG
Ocular Therapeutix
Outlook Therapeutics
Regeneron Pharmaceuticals
Sandoz Group AG
STADA Arzneimittel AG
Mighty Therapeutics
Teva Pharmaceutical Industries

Each profile includes:

Business overview
Financial and market positioning
Product and technology capabilities
Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

Custom market segmentation and forecasts
Competitive benchmarking and strategy analysis
Policy and regulatory impact assessment
Supply chain and sourcing intelligence
Scenario modelling including tariffs and geopolitical risk

Speak to our team about bespoke requirements

Why This Market Intelligence Matters

The AMD and retinal diseases drugs market is evolving rapidly, driven by longer-acting anti-VEGF therapies, first-in-class complement inhibitors, and advancing gene therapy programmes.
Organisations that understand these dynamics will be better positioned to capture commercial opportunities, manage pipeline risk, and strengthen competitive positioning.
Purchase the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Access the Full Forecast and Competitive Analysis

Purchase the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rising Prevalence of AMD in Ageing Population
3.3.1.2 Rapid Expansion of Long-Acting Anti-VEGF Launches
3.3.1.3 Improved Ophthalmic Imaging with AI-Enabled Early Detection
3.3.1.4 Increasing Healthcare Expenditure on Vision Preservation
3.3.2 Market Restraining Factors
3.3.2.1 Stringent Regulatory and Safety Requirements
3.3.2.2 High Cost of Biologics and Gene Therapies
3.3.3 Market Opportunities
3.3.3.1 Unmet Need in Dry AMD and Geography Treatment
3.3.3.2 Expansion of Nex-Generation Drug Modalities in Retinal Diseases
3.3.3.3 Growing Requirement for Safer and More Durable Retinal Therapies
3.4 U.S. Tariffs: What’s the Impact on Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Impacts As Result from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Bargaining Power of Buyer
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Disease Indication
4.1 Key Findings
4.2 Disease Indication Segment: Market Attractiveness Index
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
4.4 AMD
4.5 AMD by Type
4.5.1 Dry AMD
4.5.2 Wet AMD
4.5.3 Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
4.5.4 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.5.5 Market Share by Region, 2026 & 2036 (%)
4.6 Diabetic Macular Edema
4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 Diabetic Retinopathy
4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Retinal Vein Occlusion
4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.8.2 Market Share by Region, 2026 & 2036 (%)
4.9 Others
4.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.9.2 Market Share by Region, 2026 & 2036 (%)

5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment: Market Attractiveness Index
5.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
5.4 Intravitreal
5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Intravenous
5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Others
5.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.6.2 Market Share by Region, 2026 & 2036 (%)

6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Drug Type
6.1 Key Finding
6.2 Drug Type Segment: Market Attractiveness Index
6.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
6.4 Branded Drugs
6.5 Branded Drugs by Type
6.5.1 Eylea
6.5.2 Lucentis
6.5.3 Vabysmo
6.5.4 Others
6.5.5 Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
6.5.6 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.7 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.8 Market Share by Region, 2026 & 2036 (%)
6.6 Generic Drugs
6.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Treatment Type
7.1 Key Findings
7.2 Treatment Type Segment: Market Attractiveness Index
7.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
7.4 Anti-VEGF Agents
7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Complement Pathway Inhibitors
7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Gene & Cell Therapies
7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2026 & 2036 (%)
7.7 Dietary Supplements and Antioxidants
7.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.7.2 Market Share by Region, 2026 & 2036 (%)
7.8 Others
7.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by End-users
8.1 Key Findings
8.2 End-users Segment: Market Attractiveness Index
8.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
8.4 Hospitals
8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Ambulatory Surgical Centres
8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Speciality Clinics
8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Home Healthcare
8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.7.2 Market Share by Region, 2026 & 2036 (%)
8.8 Others
8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
10.1 Key Findings
10.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
10.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
10.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
10.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
10.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
10.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
10.8 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
10.9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
10.10 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
10.11 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

11 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.1 Key Findings
11.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
11.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
11.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
11.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
11.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
11.8 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
11.9 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
11.10 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.11 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.12 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.13 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.14 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.15 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
11.16 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

12 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.1 Key Findings
12.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
12.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
12.5 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
12.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
12.7 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
12.8 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
12.9 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
12.10 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.11 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.12 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.13 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.14 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
12.15 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

13 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
13.1 Key Findings
13.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
13.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
13.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
13.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
13.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
13.8 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
13.9 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
13.10 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
13.11 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
13.12 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

14 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
14.1 Key Findings
14.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
14.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
14.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
14.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
14.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
14.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
14.8 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
14.9 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
14.10 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
14.11 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
14.12 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

15 Company Profiles
15.1 Astellas Pharma
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2022-2025
15.1.3.2 R&D, 2022-2025
15.1.3.3 Regional Market Shares, 2025
15.1.3.4 Business Segment Market Shares, 2025
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bayer AG
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Financial Analysis
15.2.3.1 Net Revenue, 2022-2025
15.2.3.2 R&D, 2022-2025
15.2.3.3 Regional Market Shares, 2025
15.2.3.4 Business Segment Market Shares, 2025
15.2.4 Product Benchmarking
15.2.5 Strategic Outlook
15.3 Biocon
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2022-2025
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Biogen
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2022-2025
15.4.3.2 R&D, 2022-2025
15.4.3.3 Regional Market Shares, 2025
15.4.3.4 Business Segment Market Shares, 2025
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Chengdu Kanghong Biotech
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Product Benchmarking
15.6 F. Hoffmann-La Roche Ltd
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2022-2025
15.6.3.2 R&D, 2022-2025
15.6.3.3 Business Segment Market Shares, 2025
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Formycon AG
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2022-2025
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 Intas Pharmaceuticals
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.9 Kodiak Sciences
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Strategic Outlook
15.10 Novartis AG
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2022-2025
15.10.3.2 R&D, 2022-2025
15.10.3.3 Regional Market Shares, 2025
15.10.3.4 Business Segment Market Shares, 2025
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Ocular Therapeutix
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2022-2025
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Outlook Therapeutics
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Product Benchmarking
15.12.4 Strategic Outlook
15.13 Regeneron Pharmaceuticals
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2022-2025
15.13.3.2 R&D, 2022-2025
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Sandoz Group AG
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2022-2025
15.14.3.2 R&D, 2022-2025
15.14.4 Product Benchmarking
15.14.5 Strategic Outlook
15.15 STADA Arzneimittel AG
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2022-2025
15.15.4 Product Benchmarking
15.15.5 Strategic Outlook
15.16 Mighty Therapeutics
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Product Benchmarking
15.16.4 Strategic Outlook
15.17 Teva Pharmaceutical Industries
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Financial Analysis
15.17.3.1 Net Revenue, 2022-2025
15.17.3.2 R&D, 2022-2025
15.17.3.3 Regional Market Shares, 2025
15.17.4 Product Benchmarking
15.17.5 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 6 AMD Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Diabetic Macular Edema Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Diabetic Retinopathy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 Retinal Vein Occlusion Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 12 Intravitreal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 16 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Generic Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 19 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Complement Pathway Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Gene & Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 23 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End0users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 24 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Ambulatory Surgical Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Speciality Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Home Healthcare Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 31 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 32 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 33 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 34 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 35 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 36 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 37 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 38 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 39 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 40 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 41 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 42 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 43 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 44 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 45 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 46 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 47 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 48 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 49 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 50 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 51 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 53 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 54 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 55 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 56 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 57 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 58 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 59 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 60 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 61 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 62 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 63 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 64 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 65 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 66 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 67 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 68 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 69 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 70 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 71 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 72 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 73 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 74 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 75 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 76 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 77 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 78 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 79 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 80 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 81 Astellas Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Astellas Pharma: Product Benchmarking
Table 83 Astellas Pharma (Iveric Bio): Strategic Outlook
Table 84 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Bayer AG: Product Benchmarking
Table 86 Bayer AG: Strategic Outlook
Table 87 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Biocon: Product Benchmarking
Table 89 Biocon: Strategic Outlook
Table 90 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Biogen: Product Benchmarking
Table 92 Biogen: Strategic Outlook
Table 93 Chengdu Kanghong Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Chengdu Kanghong Biotech: Product Benchmarking
Table 95 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 97 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 98 Formycon AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Formycon AG: Product Benchmarking
Table 100 Formycon AG: Strategic Outlook
Table 101 Intas Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Intas Pharmaceuticals: Product Benchmarking
Table 103 Kodiak Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Kodiak Sciences: Product Benchmarking
Table 105 Kodiak Sciences: Strategic Outlook
Table 106 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Novartis AG: Product Benchmarking
Table 108 Novartis AG: Strategic Outlook
Table 109 Ocular Therapeutix: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Ocular Therapeutix: Product Benchmarking
Table 111 Ocular Therapeutix: Strategic Outlook
Table 112 Outlook Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Outlook Therapeutics: Product Benchmarking
Table 114 Outlook Therapeutics: Strategic Outlook
Table 115 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Regeneron Pharmaceuticals: Product Benchmarking
Table 117 Regeneron Pharmaceuticals: Strategic Outlook
Table 118 Sandoz Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Sandoz Group AG: Product Benchmarking
Table 120 Sandoz Group AG: Strategic Outlook
Table 121 STADA Arzneimittel AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 STADA Arzneimittel AG: Product Benchmarking
Table 123 STADA Arzneimittel AG: Strategic Outlook
Table 124 Mighty Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Mighty Therapeutics: Product Benchmarking
Table 126 Mighty Therapeutics: Strategic Outlook
Table 127 Teva Pharmaceutical Industries: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Teva Pharmaceutical Industries: Product Benchmarking
Table 129 Teva Pharmaceutical Industries: Strategic Outlook

List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Segmentation
Figure 2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Disease Indication : Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Route of Administration: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Drug Type: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Treatment Type: Market Attractiveness Index
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by End-users: Market Attractiveness Index
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Market Dynamics
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Impact Analysis
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 12 Short Term & Long Term Planning
Figure 13 Impact of U.S. and China Trade War
Figure 14 Most Impacted Countries
Figure 15 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Porter’s Five Forces Analysis
Figure 16 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: PEST Analysis
Figure 17 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Disease Indication
Figure 18 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 19 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication, 2026, 2031, 2036 (%)
Figure 20 AMD Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 21 AMD Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 22 Diabetic Macular Edema Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 23 Diabetic Macular Edema Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 24 Diabetic Retinopathy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 25 Diabetic Retinopathy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 26 Retinal Vein Occlusion Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 27 Retinal Vein Occlusion Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 29 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Disease Indication
Figure 31 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 32 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 33 Intravitreal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 34 Intravitreal Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 36 Intravenous Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 37 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 38 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Drug Type
Figure 40 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 41 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
Figure 42 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 43 Branded Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 44 Generic Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 45 Generic Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Treatment Type
Figure 47 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 48 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026, 2031, 2036 (%)
Figure 49 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 50 Anti-VEGF Agents Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Complement Pathway Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 52 Complement Pathway Inhibitors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Gene & Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 54 Gene & Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 55 Dietary Supplements and Antioxidants Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 56 Dietary Supplements and Antioxidants Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 57 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 58 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 59 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by End-users
Figure 60 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 61 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026, 2031, 2036 (%)
Figure 62 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 63 Hospitals Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 64 Ambulatory Surgical Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 65 Ambulatory Surgical Centres Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Speciality Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 67 Speciality Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 Home Healthcare Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 69 Home Healthcare Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 70 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 71 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 72 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 73 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 74 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Mn)
Figure 75 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
Figure 76 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 77 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 78 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 79 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 80 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
Figure 81 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 82 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 83 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 84 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 85 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 86 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
Figure 87 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 88 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 89 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 90 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 91 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
Figure 92 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 93 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 94 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 95 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 96 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
Figure 97 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 98 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 99 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 100 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 101 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 102 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
Figure 103 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 104 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 105 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 106 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 107 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 108 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 109 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 111 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 112 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
Figure 113 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 114 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 115 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 116 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 117 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
Figure 118 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 119 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 120 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 121 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 122 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 123 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
Figure 124 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 125 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 126 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 127 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 128 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 129 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 130 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 131 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 132 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
Figure 133 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 134 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 135 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 136 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 137 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
Figure 138 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 139 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 140 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 141 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 142 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 143 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
Figure 144 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 145 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 146 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 147 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 148 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 149 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
Figure 150 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 151 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 152 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 153 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
Figure 154 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
Figure 155 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 156 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 157 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 158 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 159 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
Figure 160 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
Figure 161 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 162 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 163 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 164 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 165 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 166 Astellas Pharma: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 167 Astellas Pharma: R&D, 2022-2025 (US$ Million, AGR %)
Figure 168 Astellas Pharma: Regional Market Shares (%), 2025
Figure 169 Astellas Pharma: Business Segment Market Shares (%), 2025
Figure 170 Bayer AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 171 Bayer AG: R&D, 2022-2025 (US$ Million, AGR %)
Figure 172 Bayer AG: Regional Market Shares (%), 2025
Figure 173 Bayer AG: Business Segment Market Shares (%), 2025
Figure 174 Biocon: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 175 Biogen: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 176 Biogen: R&D, 2022-2025 (US$ Million, AGR %)
Figure 177 Biogen: Regional Market Shares (%), 2025
Figure 178 Biogen: Business Segment Market Shares (%), 2025
Figure 179 F. Hoffmann-La Roche Ltd: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 180 F. Hoffmann-La Roche Ltd: R&D, 2022-2025 (US$ Million, AGR %)
Figure 181 F. Hoffmann-La Roche Ltd: Business Segment Market Shares (%), 2025
Figure 182 Formycon AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 183 Novartis AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 184 Novartis AG: R&D, 2022-2025 (US$ Million, AGR %)
Figure 185 Novartis AG: Regional Market Shares (%), 2025
Figure 186 Novartis AG: Business Segment Market Shares (%), 2025
Figure 187 Ocular Therapeutix: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 188 Regeneron Pharmaceuticals: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 189 Regeneron Pharmaceuticals: R&D, 2022-2025 (US$ Million, AGR %)
Figure 190 Regeneron Pharmaceuticals: Regional Market Shares (%), 2025
Figure 191 Regeneron Pharmaceuticals: Business Segment Market Shares (%), 2025
Figure 192 Sandoz Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 193 Sandoz Group AG: R&D, 2022-2025 (US$ Million, AGR %)
Figure 194 STADA Arzneimittel AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 195 Teva Pharmaceutical Industries: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 196 Teva Pharmaceutical Industries: R&D, 2022-2025 (US$ Million, AGR %)
Figure 197 Teva Pharmaceutical Industries: Regional Market Shares (%), 2025

List of Companies Profiled in the Report
Apellis Pharmaceuticals
Astellas Pharma
Bayer AG
Biocon
Biogen
Chengdu Kanghong Biotech
F. Hoffmann-La Roche Ltd
Formycon AG
Intas Pharmaceuticals
Kodiak Sciences
Novartis AG
Ocular Therapeutix
Outlook Therapeutics
Regeneron Pharmaceuticals
Sandoz Group AG
STADA Arzneimittel AG
Mighty Therapeutics
Teva Pharmaceutical Industries

List of Other Companies Mentioned in the Report
4D Molecular Therapeutics
Adani Group
Adverum Biotechnologies
Alvotech
Apotex
Bayer
Boehringer Ingelheim
Cirrus Therapeutics
Coave Therapeutics
Complement Therapeutics
Everest Medicines
Klinge Biopharma GmbH
Luxa Biotechnology
MeiraGTx
MingMed Biotechnology
Nanoscope Therapeutics
Ocugen Inc.
ONL Therapeutics
Otsuka Pharmaceutical
Palatin Technologies
Perfuse Therapeutics
PSK Pharma
RemeGen
Stealth BioTherapeutics Inc.
ZipBio
Zydus Lifesciences

List of Associations Mentioned in the Report
American Academy of Ophthalmology (AAO)
American Macular Degeneration Foundation (AMDF)
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
European Medicines Agency (EMA)
European Society of Retina Specialists (EURETINA)
Foundation Fighting Blindness
International Agency for the Prevention of Blindness (IAPB)
Macular Disease Foundation Australia
Macular Society
National Eye Institute (NEI)
National Institutes of Health (NIH)
Retina International
United States Food and Drug Administration (FDA)
World Health Organization (WHO)

Industry Market Reports